Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 9/20 | 0.54 |
| ▸ | CCND1 | P24385 | 9/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.54 |
| ▸ | CDK1 | P06493 | 4/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.54 |
| ▸ | CDK2 | P24941 | 11/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.48 |
| ▸ | CCND3 | P30281 | 2/20 | 0.48 |
| ▸ | CDK7 | P50613 | 2/20 | 0.48 |
| ▸ | CDK9 | P50750 | 2/20 | 0.48 |
| ▸ | CCNH | P51946 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254089 | 0.86 | CDK4 (0.68) | CDK4CCND1CDK6CDK1CCNB1 | |
| SCHEMBL4254071 | 0.77 | CDK2 (0.81) | CDK4CCND1CDK6CDK1CCNB1 | |
| SCHEMBL4254074 | 0.77 | CDK2 (0.81) | CDK4CCND1CDK6CDK1CCNB1 | |
| SCHEMBL3548674 | 0.76 | CDK2 (0.80) | CDK4CCND1CDK6CDK1CCNB1 | |
| SCHEMBL27701541 | 0.76 | CDK2 (0.62) | CDK4CCND1CDK6CDK1CCNB1 | |
| SCHEMBL4255345 | 0.74 | CDK2 (0.79) | CDK4CCND1CDK6CDK1CCNB1 | |
| SCHEMBL5380216 | 0.72 | CDK2 (0.72) | CDK4CCND1CDK6CDK1CCNB1 | |
| SCHEMBL4245323 | 0.72 | CDK4 (0.62) | CDK4CCND1CDK6CDK1CCNB1 | |
| SCHEMBL4246292 | 0.71 | CDK2 (0.67) | CDK4CCND1CDK6CDK1CCNB1 | |
| SCHEMBL4248546 | 0.70 | CDK2 (0.37) | CDK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | MKI67, TYMP, PCNA | CDK4 30/4885CCND1 38/4885CDK6 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.